Lung cancer management in 2010

Apar Kishor Ganti; Chao H. Huang; Mark A. Klein; Sean Keefe; Michael J. Kelley

Lung cancer management in 2010

Apar Kishor Ganti, Chao H. Huang, Mark A. Klein, Sean Keefe, Michael J. Kelley

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

Original language	English (US)
Journal	ONCOLOGY
Volume	25
Issue number	1
State	Published - Jan 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{be40b54143c64d18a79a7e1d46e08c92,

title = "Lung cancer management in 2010",

abstract = "The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.",

author = "Ganti, {Apar Kishor} and Huang, {Chao H.} and Klein, {Mark A.} and Sean Keefe and Kelley, {Michael J.}",

year = "2011",

month = jan,

language = "English (US)",

volume = "25",

journal = "ONCOLOGY",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "1",

}

TY - JOUR

T1 - Lung cancer management in 2010

AU - Ganti, Apar Kishor

AU - Huang, Chao H.

AU - Klein, Mark A.

AU - Keefe, Sean

AU - Kelley, Michael J.

PY - 2011/1

Y1 - 2011/1

N2 - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

AB - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=79551718343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551718343&partnerID=8YFLogxK

M3 - Review article

C2 - 21361246

AN - SCOPUS:79551718343

SN - 0890-9091

VL - 25

JO - ONCOLOGY

JF - ONCOLOGY

IS - 1

ER -

Lung cancer management in 2010

Abstract

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this